Kiro
- Company typePrivate
- Founded2019
- HeadquartersParis, France
- Headcount11–50
- GTM typeB2B and B2C
- OfferingSoftware
Kiro firmographics
Firmographics- Name
- Kiro
- Legal name
- Kiro
- Website
- https://www.kiro.bio
- Company type
- Private
- Founded year
- 2019
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Ownership category
- akta.pro rank
Kiro industry classification
Industry- Product category
- Clinical Decision Support Software
- NAICS
- Software Publishers (5132), Software Publishers (513210)
- SIC
- Services-Computer Processing & Data Preparation (7374), Services-Medical Laboratories (8071)
- akta.pro primary industry
- Electronic Lab Notebooks (ELN) (HLAGAJAB)
Keywords
Where Kiro is headquartered
LocationHeadquarters
- HQ city
- Paris
- HQ country
- France
- HQ region
- Europe
Offices1 record
Markets served
Kiro business model
Business model- GTM type
- B2B and B2C
- Offering type
- Software
- Cost components
- Personnel, Technology or R&D, Marketing or Sales, Infrastructure, Operations
Revenue model
- B2B Healthcare Platform Licensing: Kiro provides AI-powered diagnostic solutions to laboratories, hospitals, and healthcare organizations. The platform is deployed across clinical sites with integration into existing hospital and laboratory systems, likely through enterprise licensing agreements.
- Direct-to-Consumer App: Mobile application for patients to access, understand, and track their biological test results over time. Available on iOS and Android app stores.
Pricing tiers
| Model | Billing | Price |
|---|---|---|
| Subscription | Annual | Enterprise healthcare platform pricing |
Go-to-market motion2 records
Distribution channels3 records
Marketing channels6 records
Kiro product offering
Product offeringCore offering
Kiro provides an AI-powered clinical biology platform that converts fragmented laboratory data into structured clinical knowledge, combining medical literature, lab results and clinical guidelines into medically validated insights. It delivers its capabilities through two channels: a CE-marked B2B platform (BEYOND® clinical decision support and Kiro for Healthcare Professionals) deployed across hospital and laboratory networks, and a direct-to-consumer mobile application that enables patients to access, understand and track their biological test results over time.
Product overview
Kiro is a digital health platform consisting of the Kiro App (a CE-marked medical device for patients to understand biological test results) and Kiro for Healthcare Professionals (a B2B solution for clinical diagnostics). The platform integrates a proprietary AI system called BEYOND® that provides clinical decision support. The ecosystem connects patients, laboratories, and hospitals through interoperability standards (FHIR, HL7, LOINC), processing over 1.4 billion biological results from 3+ million users across 280+ clinical sites in Europe.
Differentiator
Problem solved
Functional benefit
Brands
- BEYOND: An AI-powered clinical decision support system that can preliminarily recommend medical and/or biological tests based on medical examinations and clinical data. Achieved 88% balanced accuracy, +10 points in sensitivity vs baseline physician performance, and 99% specificity.
Products and services
- Kiro App CE-marked medical device mobile application that gives patients same-day access to their biological test results with personalized, clinically grounded explanations, longitudinal health timeline tracking, and PDF export to share with providers. Designed for individuals who want to better understand and follow their lab results.
- Kiro for Healthcare Professionals B2B AI platform for laboratories, hospitals and healthcare organizations that improves diagnostic workflows, optimizes appropriate test utilization, supports clinical decision-making, and enhances patient engagement through integration into existing hospital and laboratory information systems. Designed for clinical teams who need to standardize and digitalize biological result delivery at scale.
- BEYOND® Clinical Decision Support AI CE-marked AI clinical decision support system that preliminarily recommends medical and biological tests based on medical examinations and clinical data. Designed for clinicians and healthcare organizations seeking to improve appropriateness of test ordering and follow-up decisions.
Quantifiable outcome
- 88% balanced accuracy for BEYOND® AI test recommendation system
- +5 more outcomes
Companies that use Kiro
Customer profileNamed customers14 records
Segments4 records
Ideal customer profiles4 records
Kiro technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
AI capability5 records
Feature8 records
Kiro partnerships and signals
Strategic signalPartnerships
Twelve partnerships are on record, tiered core and minor.
- UnilabscoreLeading European medical diagnostics company partnering with Kiro to provide digital access to biological test results for patients across their laboratory network.
- American Hospital of PariscorePrestigious private hospital in France deploying Kiro's diagnostic AI platform to improve patient care and laboratory medicine accessibility.
- Synlab ProvencecoreMajor laboratory network in Provence, France partnering with Kiro for digital biology services.
- MedipathcoreLaboratory network partner distributing Kiro's platform to patients.
- Assistance Publique — Hôpitaux de Marseille (AP-HM)coreMajor public hospital system in Marseille integrating Kiro's clinical AI into hospital workflows for improved diagnostic decision support.
- Geneva University Hospitals (HUG)coreLeading Swiss university hospital integrating Kiro's diagnostic AI platform for enhanced laboratory medicine capabilities.
- LabiocoreLaboratory services partner offering Kiro's digital biology platform to patients.
- CHU de LimogescoreUniversity Hospital of Limoges partnering with Kiro for clinical AI integration.
- AstraZenecaminorPharmaceutical company collaborating on digital health programs and patient engagement initiatives with Kiro.
- Pfizer Healthcare HubminorPfizer's healthcare innovation hub partnering with Kiro for digital health initiatives.
- LabologyminorLaboratory services partner offering Kiro's platform to their customer base.
- Unibio 92minorLaboratory network partner in the 92 department of France.
Scale indicators9 records
Recent moves6 records
Expansion highlights6 records
Kiro competitors and assessment
Company assessmentDirect peers
- Owkin: French AI-for-biology company applying machine learning to clinical and biomedical data for hospitals and pharma. Comparable on AI applied to clinical biology, real-world data advantage, and European healthcare-pharma bridge, though Kiro is patient-facing where Owkin is more research-facing.
- Tribun Health: European digital pathology and lab-medicine AI vendor serving hospital pathology departments. Comparable as a CE-marked AI software vendor selling into hospital and laboratory workflows, with similar clinical validation, regulatory, and channel-sale challenges.
- Lifen: French health-data platform that digitizes and shares medical documents between hospitals, labs, and patients. Most direct functional peer to Kiro in the French market, addressing the same fragmented lab/hospital document problem and targeting the same lab and hospital buyer.
- Lunit: Medical AI company with CE-marked and FDA-cleared clinical decision-support algorithms sold to hospitals and labs globally. Comparable as a clinically validated AI medical-device vendor pursuing the lab-and-hospital GTM and similar geographic expansion strategy (Europe + US).
- Ada Health: AI-driven consumer health companion app that helps individuals understand symptoms and test results. Comparable on the patient-facing AI interpretation layer, mobile-first UX, and the hybrid B2C/B2B monetization model, though Ada is symptom-led while Kiro is lab-led.
Broad incumbents
- IQVIA: Global healthcare data, analytics, and technology provider serving pharma, providers, and labs. Comparable in its use of large real-world clinical datasets to deliver insights to pharma and providers, and as a potential acquirer or channel partner for Kiro's pharma and lab businesses.
- Tempus: US-based AI precision-medicine company that processes large volumes of clinical and molecular data to support providers and pharma. Comparable in its AI-on-clinical-biology thesis, real-world-data advantage, and dual pharma/provider business model, though Tempus is much larger and oncology-focused.
- Doctolib: Dominant French digital health platform for appointment booking, teleconsultation, and patient/provider communication. A much larger incumbent that competes for the same healthcare-organization IT budget and increasingly patient-engagement mindshare, even though it does not focus on lab-result interpretation.
Emerging players
- Withings: French consumer health-tech company producing connected devices and a health-data app. Comparable as a French-headquartered consumer health platform that aggregates and contextualizes personal health data, though it focuses on device data rather than lab data.
- Nabla: AI assistant for clinicians, focused on ambient clinical documentation and decision support. Comparable as a French and US-based AI clinical-decision-support vendor pursuing similar healthcare-organization customers with similar regulatory and accuracy-validation narratives.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat7 records
Key risks6 records
Key highlights7 records
Customer concentration
Kiro compliance and trust
Trust signalCompliance5 records
Kiro financial estimates
Financial estimateRevenue estimate
Valuation estimate
Kiro leadership team
Management profileNumber of profiles
Profiles5 records
Kiro funding detail
Funding detailFunding overview
Funding rounds1 record
Investors5 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Kiro M&A and investment
M&A and investmentM&A
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Kiro
What does Kiro do?
Kiro provides an AI-powered clinical biology platform that converts fragmented laboratory data into structured clinical knowledge, combining medical literature, lab results and clinical guidelines into medically validated insights. It delivers its capabilities through two channels: a CE-marked B2B platform (BEYOND® clinical decision support and Kiro for Healthcare Professionals) deployed across hospital and laboratory networks, and a direct-to-consumer mobile application that enables patients to access, understand and track their biological test results over time.
Is Kiro a public or private company?
Kiro is a private company. It is classified as venture growth investor backed and is currently operating.
When was Kiro founded?
Kiro was founded in 2019. It employs 11 to 50 people.
Where is Kiro based?
Kiro is headquartered in Paris, France, in the Europe region.
How does Kiro make money?
Two revenue lines are on record. B2B Healthcare Platform Licensing is the primary driver. The others are direct-to-Consumer App.
Who are Kiro's main competitors?
Direct peers on record are Owkin, Tribun Health, Lifen, Lunit and Ada Health. Broad incumbents are IQVIA, Tempus and Doctolib. Emerging players are Withings and Nabla.
Does Kiro have an API?
No public API is recorded for Kiro.
What industry is Kiro in?
Kiro's product category is Clinical Decision Support Software. Its primary akta.pro industry code is HLAGAJAB, Electronic Lab Notebooks (ELN). Its NAICS code is 5132 and its SIC code is 7374.